The Effect of Vitamin D3 Supplementation on Serum BDNF, Dopamine, and Serotonin in Children with Attention-Deficit/Hyperactivity Disorder.

What Was Tested

This clinical trial looks at Vitamin D, K2, Magnesium and Zinc.

Attention-Deficit/Hyperactivity Disorder (ADHD) is one of the most common psychiatric disorders in childhood.

The exact etiology of this disease is unknown, but it is believed to be related to the disorder of catecholaminergic and serotonergic systems.

Also, serum vitamin D levels in patients with ADHD is lower.

Who Took Part

PubMed indexes the participants as children, both men and women.

Eighty-six children with ADHD were divided into two groups, based on randomized permuted blocks.

How the Study Was Run

In design terms this was a randomized and placebo-controlled study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Some participants received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

Serum levels of BDNF, dopamine, serotonin, and 25-hydroxyvitamin D [25(OH)D] were measured at baseline and at the end of the study.

What Was Measured

PubMed files the paper under topics including Attention Deficit Disorder with Hyperactivity, Brain-Derived Neurotrophic Factor, Cholecalciferol, Dietary Supplements, Dopamine and Serotonin.

The authors tagged it with the keywords Attention-deficit/hyperactivity disorder, supplementation and vitamin D.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

Results are reported in around 3 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2019 (CNS & neurological disorders drug targets), a journal based in United Arab Emirates.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.